Poor
Not Aligned
Patient Risk:
High
Summary
Some indication/mechanism statements align with the provided label excerpts (Sections 1.1–1.3 and 12.1). However, the response includes many hypertension/vasopressin/kidney-function/monitoring and management claims that are not supported by the provided labeling text and lack any label citations, making overall alignment poor.
Category Scores
Accurate Statements
Cosentyx is also known as secukinumab.
Supported by label excerpt: 12.1 Mechanism of Action (Secukinumab binding to IL-17A).
Cosentyx is a biologic medication that targets interleukin-17A (IL-17A).
Supported by label excerpt: 12.1 Mechanism of Action.
IL-17A is involved in the inflammatory response.
Supported by label excerpt: 12.1 Mechanism of Action (normal inflammatory and immune responses).
Cosentyx is used to treat moderate to severe plaque psoriasis.
Supported by label excerpt: 1.1 Plaque Psoriasis.
Cosentyx is used to treat psoriatic arthritis.
Supported by label excerpt: 1.2 Psoriatic Arthritis.
Cosentyx is used to treat ankylosing spondylitis.
Supported by label excerpt: 1.3 Ankylosing Spondylitis.
Cosentyx blocks the action of IL-17A.
Supported by label excerpt: 12.1 (selectively binds IL-17A and inhibits its interaction with the IL-17 receptor).
Blocking IL-17A helps reduce inflammation.
Supported by label excerpt: 12.1 (inhibits release of proinflammatory cytokines and chemokines).
Cosentyx works by reducing inflammation.
Supported by label excerpt: 12.1 (inhibits proinflammatory cytokines and chemokines).
Unsupported Statements
Blocking IL-17A helps slow down disease progression.
Not supported by the provided label excerpts.
Patients taking Cosentyx had a higher risk of developing high blood pressure compared to those taking placebo.
No hypertension/high blood pressure risk information is present in the provided label excerpts.
The exact mechanism by which Cosentyx increases the risk of high blood pressure is not fully understood.
No hypertension mechanism discussion is present in the provided label excerpts.
Reducing inflammation can lead to changes in blood vessel function that increase blood pressure.
No such mechanistic explanation is present in the provided label excerpts.
Cosentyx may increase the levels of vasopressin.
No vasopressin-related information is present in the provided label excerpts.
Vasopressin is a hormone that helps regulate blood pressure.
No vasopressin-related information is present in the provided label excerpts.
Elevated vasopressin levels can lead to increased blood pressure.
No vasopressin/causality information is present in the provided label excerpts.
Cosentyx may affect kidney function.
No kidney-function related information is present in the provided label excerpts.
Changes in kidney function can affect blood pressure regulation.
No kidney-function-to-blood-pressure linkage is present in the provided label excerpts.
Patients taking Cosentyx had a higher incidence of high blood pressure compared to those taking other biologic medications.
No comparative hypertension incidence data is present in the provided label excerpts.
Cosentyx was associated with an increased risk of hypertension in patients with psoriatic arthritis.
No hypertension association data by indication is present in the provided label excerpts.
There is a concern that Cosentyx may have side effects including high blood pressure.
No hypertension adverse reaction/concern statement is present in the provided label excerpts.
High blood pressure is a potential side effect of Cosentyx that requires close monitoring.
No hypertension monitoring/side effect language is present in the provided label excerpts.
The absolute risk of high blood pressure with Cosentyx is still relatively low.
No absolute risk information is present in the provided label excerpts.
Patients taking Cosentyx should be closely monitored for signs of high blood pressure.
No hypertension monitoring instruction is present in the provided label excerpts.
Regular blood pressure checks can help identify any potential issues early.
No blood pressure-check monitoring instruction is present in the provided label excerpts.
Lifestyle modifications can help reduce the risk of high blood pressure.
No lifestyle-modification guidance related to hypertension is present in the provided label excerpts.
If high blood pressure is detected, a healthcare provider may adjust Cosentyx dosage or add other medications to help manage blood pressure.
No dosing-adjustment/additional-medication guidance for hypertension is present in the provided label excerpts.
If you have high blood pressure, you should discuss treatment options with your healthcare provider.
No hypertension-specific counseling language is present in the provided label excerpts.
A healthcare provider may recommend alternative treatments or adjust Cosentyx dosage to minimize the risk of high blood pressure.
No hypertension-specific alternative/dose-adjustment counseling is present in the provided label excerpts.
If you experience high blood pressure while taking Cosentyx, contact your healthcare provider immediately.
No hypertension-specific contact instruction is present in the provided label excerpts.
A healthcare provider may adjust the treatment plan or add medications to help manage blood pressure if high blood pressure occurs while taking Cosentyx.
No hypertension-specific treatment-plan modification guidance is present in the provided label excerpts.
Contradictions
Important Omissions
The response does not provide dosing/administration instructions, contraindications, boxed warning content, or detailed warnings/precautions from the label (Sections not included in the provided excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple safety-related statements about hypertension risk, mechanism (vasopressin/kidney function), and monitoring/management are unsupported by the provided label excerpts, which could mislead safety communication and monitoring actions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Hypertension/vasopressin/kidney-function and related monitoring/management claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or revise unsupported hypertension-related claims unless the full label sections containing adverse reactions and monitoring guidance are provided; restrict claims to the supported label excerpts (Indications 1.1–1.3 and Mechanism 12.1).